Directory

Jacob Corn

Professor of Genome Biology | PhD | Berkeley, USA

The Corn Lab develops and uses next-generation genome editing and regulation technologies. They work on both fundamental biological discovery and potential therapies for human genetic diseases. Our focus is the mechanisms by which cells repair their DNA, maintain and differentiate hematopoietic stem cells, and use ubiquitin signaling to propagate cellular signals. Through technology development, mechanistic cellular biochemistry, and translational projects, they are working to unravel complex cellular phenotypes to further biological understanding and improve human health.

Jacob is committed to the improvement of human health through the fundamental understanding of disease mechanisms. Over the last fifteen years he has bridged academia and industry, working in therapeutic areas that include infectious disease, neurobiology, and oncology. His graduate studies at the University of California, Berkeley redefined our understanding of DNA replication and his postdoctoral work at the University of Washington computationally designed protein inhibitors from scratch. Prior to joining the Innovative Genomics Institute, Jacob was a group leader at Genentech where he discovered biological mechanisms for challenging therapeutic targets. In his spare time, Jacob enjoys long backpacking trips and rock climbing.

The Latest

News & Events

Behind the Research: Andrew Deans

My lab’s vision for the next five years is to apply what we have learned to develop molecules that can alter FA protein behavior. These could be used to treat cancer or alter gene editing outcomes.

Read More >

Breaking Ground in Cancer Research: Introducing the Fanconi Cancer Foundation-AACR NextGen Grant

That's why we're thrilled to announce the launch of the Fanconi Cancer Foundation-AACR NextGen Grant for Transformative Cancer Research, a flagship funding opportunity in partnership with the American Association for Cancer Research (AACR).

Read More >

Introducing the Fanconi Cancer Foundation: A New Era in FA Research & Impact

In 1989, Lynn and David Frohnmayer founded the Fanconi Anemia Research Fund (FARF), determined and desperate to find a cure for their three daughters diagnosed with Fanconi anemia (FA). Since then, their vision has grown into a vibrant community of FA families, researchers, clinicians, donors, fundraisers, staff, and volunteers, all dedicated to improving outcomes for people with FA.

Read More >